Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (281-290 of 440) with videos related to

Pageof 44
Sort By:
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
The Journal of Clinical Investigation|August 5, 2025
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapyAlyssa M Duffy, Anshika Goenka, Maryam I Azeem, et al.
The Journal of Clinical Investigation|August 27, 2019
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradationChaoyun Pan, Jaemoo Chun, Dan Li, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Nucleic Acids Research|January 31, 2016
Gene integrated set profile analysis: a context-based approach for inferring biological endpointsJeanne Kowalski, Bhakti Dwivedi, Scott Newman, et al.
British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.
Pageof 44

Showing results (281-290 of 440) with videos related to

Sort By:
Pageof 44
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
The Journal of Clinical Investigation|August 5, 2025
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapyAlyssa M Duffy, Anshika Goenka, Maryam I Azeem, et al.
The Journal of Clinical Investigation|August 27, 2019
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradationChaoyun Pan, Jaemoo Chun, Dan Li, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Nucleic Acids Research|January 31, 2016
Gene integrated set profile analysis: a context-based approach for inferring biological endpointsJeanne Kowalski, Bhakti Dwivedi, Scott Newman, et al.
British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.
Pageof 44